

MAR 18 2003

Substitute PTO/SB/8A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO
(Modified)INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Completeness

Application Number	09/653,924
Filing Date	September 1, 2000
First Named Inventor	HORWITZ, David A.
Group Art Unit	1644
Examiner Name	HADDAD, Maher M.
Attorney Docket Number	A-67689-3/RFT/RMS/RMK (469443-11)

U.S. PATENT DOCUMENTS

Examiner Initials*	Citation No.	U.S. Patent Document Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1				
	A2				
	A3				
	A4				
	A5				
	A6				
	A7				
	A8				
	A9				
	A10				
	A11				

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Citation No.	Foreign Patent Document Country Code ² Number ² Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
	B1					
	B2					
	B3					
	B4					
	B5					
	B6					

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Citation No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ³
	C1	HEITGER A, et al. "Essential role of the thymus to reconstitute naive (CD45RA+) T-helper cells after human allogeneic bone marrow transplantation." Blood. 1997 Jul 15;90(2):850-7.	
	C2	CHEN W, et al. "T cells specific for a polymorphic segment of CD45 induce graft-versus-host disease with predominant pulmonary vasculitis." J Immunol. 1998 Jul 15;161(2):909-18.	
	C3	EARLY E, and Reen DJ. "Rapid conversion of naive to effector T cell function counteracts diminished primary human newborn T cell responses." Clin Exp Immunol. 1999 Jun;116(3):527-33. (Abstract)	
	C4	GARDERET L, et al. "Effective depletion of alloreactive lymphocytes from peripheral blood mononuclear cell preparations." Transplantation. 1999 Jan 15;67(1):124-30.	
	C5		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 1106579_1.DOC